びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬の世界市場（2025年）

世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬の市場規模は、今後数年間に力強い成長が見込まれており、2029年に70億5,000万米ドルに達すると予測され、CAGRで8.2%の成長が見込まれます。予測期間の成長は、バイオマーカーの発見、免疫療法の進歩、罹患率の上昇、世界的な高齢化、医療インフラの開発、新薬へのアクセスの拡大などに起因すると考えられます。予測期間における主要動向は、外来治療環境の増加、共同臨床試験、患者中心のケアモデル、画像診断の進歩、医療のデジタル化などです。

びまん性大細胞型B細胞リンパ腫（DLBCL）の有病率の上昇は、びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場の拡大を促進すると予測されます。びまん性大細胞型B細胞リンパ腫（DLBCL）は、リンパ系のB細胞から発生する非ホジキンリンパ腫の侵攻型であり、急速でびまん性の増殖を特徴とします。DLBCL向けに開発された治療薬は、がん細胞を効果的に標的とし管理することで、患者の予後を改善することを目的としています。注目すべきことに、American Cancer Societyの2023年の予測では、新たに約8万550人の非ホジキンリンパ腫患者が発生すると予測されており、治療ソリューションの進歩が緊急に必要であることが強く示されています。このような罹患率の増加は、びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場の成長のカタリストとなっています。

びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場の今後の成長は、個別化医療の採用の増加と密接に結びついています。革新的な医療アプローチである個別化医療は、遺伝子や分子プロファイルを含む各患者の固有の特性に合わせた医学的介入を行います。このアプローチは、DLBCLサブタイプの不均一性に特異的に対処する標的療法の開発を促進します。バイオマーカー主導の治療戦略とコンパニオン診断は、特定の治療が有効である可能性の高い患者を同定し、全体的な治療効果を高める上で極めて重要な役割を果たします。注目すべきは、2022年に米国食品医薬品局（FDA）の医薬品評価研究センター（CDER）が37の新規分子化合物（NME）を承認し、その約34%（12のNME）がPersonalized Medicine Coalition（PMC）によって個別化医療に分類されたことです。個別化医療の採用の増加は、びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場の成長の重大な促進要因として浮上しています。

当レポートでは、世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場について調査分析し、市場の特徴、市場の動向と戦略、各地域の分析、競合情勢などの情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場の特徴

第3章 びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場の動向と戦略

第4章 びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場 - 市場に対する金利、インフレ、地政学、COVIDと回復の影響を含むマクロ経済シナリオ

第5章 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬の成長分析、戦略的分析フレームワーク

• 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場の成長率分析
• 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬の市場規模と成長の実績（2019年～2024年）
• 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬の市場規模と成長の予測（2024年～2029年・2034年）
• 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬の市場規模（TAM）

第6章 びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場のセグメンテーション

• 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場：薬剤クラス別、実績と予測（2019年～2024年・2024年～2029年・2034年）
• シスプラチン
• カルボプラチン
• 5-フルオロウラシル
• ドセタキセル
• パクリタキセル
• メトトレキサート
• その他の薬剤
• 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場：治療法別、実績と予測（2019年～2024年・2024年～2029年・2034年）
• 標的療法
• 免疫療法
• 化学療法
• その他の治療法
• 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場：投与経路別、実績と予測（2019年～2024年・2024年～2029年・2034年）
• 経口
• 非経口
• その他の経路
• 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場：エンドユーザー別、実績と予測（2019年～2024年・2024年～2029年・2034年）
• 病院
• 診療所
• その他のエンドユーザー
• 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場、シスプラチンのサブセグメンテーション：タイプ別、実績と予測（2019年～2024年・2024年～2029年・2034年）
• 注射剤
• 併用療法
• 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場、カルボプラチンのサブセグメンテーション：タイプ別、実績と予測（2019年～2024年・2024年～2029年・2034年）
• 注射剤
• 併用療法
• 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場、5-フルオロウラシルのサブセグメンテーション：タイプ別、実績と予測（2019年～2024年・2024年～2029年・2034年）
• 注射剤
• 経口剤
• 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場、ドセタキセルのサブセグメンテーション：タイプ別、実績と予測（2019年～2024年・2024年～2029年・2034年）
• 注射剤
• 併用療法
• 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場、パクリタキセルのサブセグメンテーション：タイプ別、実績と予測（2019年～2024年・2024年～2029年・2034年）
• 注射剤
• 併用療法
• 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場、メトトレキサートのサブセグメンテーション：タイプ別、実績と予測（2019年～2024年・2024年～2029年・2034年）
• 注射剤
• 経口剤
• 併用療法
• 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場、その他の薬剤のサブセグメンテーション：タイプ別、実績と予測（2019年～2024年・2024年～2029年・2034年）
• モノクローナル抗体
• 標的療法
• 免疫療法
• 実験的治療法

第7章 びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場の地域と国の分析

• 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場：地域別、実績と予測（2019年～2024年・2024年～2029年・2034年）
• 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場：国別、実績と予測（2019年～2024年・2024年～2029年・2034年）

第8章 アジア太平洋のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第9章 中国のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第10章 インドのびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第11章 日本のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第12章 オーストラリアのびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第13章 インドネシアのびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第14章 韓国のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第15章 西欧のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第16章 英国のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第17章 ドイツのびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第18章 フランスのびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第19章 イタリアのびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第20章 スペインのびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第21章 東欧のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第22章 ロシアのびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第23章 北米のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第24章 米国のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第25章 カナダのびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第26章 南米のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第27章 ブラジルのびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第28章 中東のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第29章 アフリカのびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場

第30章 びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場の競合情勢と企業プロファイル

• びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場の競合情勢
• びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場の企業プロファイル
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co Inc.
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche AG

第31章 びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場のその他の主要企業と革新的企業

• CTI BioPharma Corp.
• Celltrion Healthcare Co Ltd.
• Bristol-Myers Squibb Company
• AbbVie Inc.
• Gilead Sciences Inc.
• Seagen Inc.
• Kite Pharma Inc.
• ADC Therapeutics SA
• Bayer AG
• Xencor Inc.
• Autolus Therapeutics plc
• Allogene Therapeutics Inc.
• Spectrum Pharmaceuticals Inc.
• AstraZeneca PLC
• Aptevo Therapeutics Inc.

第32章 世界のびまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場の競合ベンチマーキングとダッシュボード

第33章 びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場における主な合併と買収

第34章 びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場の近年の発展

第35章 びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場の潜在的可能性の高い国、セグメント、戦略

• びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場 - もっとも新しい機会を提供する国（2029年）
• びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場 - もっとも新しい機会を提供するセグメント（2029年）
• びまん性大細胞型B細胞リンパ腫（DLBCL）治療薬市場 - 成長戦略（2029年）
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Diffuse large B-cell lymphoma therapeutics encompass the strategies and pharmaceutical interventions employed to address and counteract diffuse large B-cell lymphoma, an aggressive subtype of non-Hodgkin lymphoma characterized by the rapid proliferation of malignant B-cells.

Key pharmaceutical categories integral to the treatment of diffuse large B-cell lymphoma include cisplatin, carboplatin, 5-fluorouracil (5-FU), docetaxel (Taxotere), paclitaxel (Taxol), methotrexate, among others. Cisplatin is a chemotherapeutic agent utilized across various malignancies due to its mechanism of disrupting cancer cell DNA, thereby impeding their proliferative capacity. In the context of lymphoma management, cisplatin is often incorporated into combination chemotherapy protocols. The therapeutic regimen encompasses a spectrum of modalities such as targeted therapy, immunotherapy, and chemotherapy, administered via oral, parenteral, and alternative routes. These treatments are typically dispensed within hospital and clinical settings.

The diffuse large B-cell lymphoma market research report is one of a series of new reports from The Business Research Company that provides diffuse large B-cell lymphoma market statistics, including the diffuse large B-cell lymphoma industry global market size, regional shares, competitors with a diffuse large B-cell lymphoma market share, detailed diffuse large B-cell lymphoma market segments, market trends, and opportunities, and any further data you may need to thrive in the diffuse large B-cell lymphoma industry. This diffuse large B-cell lymphoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The diffuse large B-cell lymphoma therapeutics market size has grown strongly in recent years. It will grow from$4.74 billion in 2024 to $5.15 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to clinical research advances, regulatory approvals, patient awareness and diagnosis, collaborative initiatives, standard of care evolution

The diffuse large B-cell lymphoma therapeutics market size is expected to see strong growth in the next few years. It will grow to $7.05 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to biomarker discovery, immunotherapy advancements, rising incidence rates, global aging population, healthcare infrastructure development, expanded access to novel drugs. Major trends in the forecast period include rise of outpatient treatment settings, collaborative clinical trials, patient-centric care models, advances in diagnostic imaging, healthcare digitalization.

The rising prevalence of diffuse large B-cell lymphoma (DLBCL) is anticipated to propel the expansion of the diffuse large B-cell lymphoma therapeutics market. DLBCL, an aggressive form of non-Hodgkin lymphoma originating from B-cells in the lymphatic system, is characterized by rapid and diffuse growth. The therapeutics developed for DLBCL aim to enhance outcomes for diagnosed individuals by effectively targeting and managing cancer cells. Notably, the American Cancer Society's 2023 estimates project approximately 80,550 new non-Hodgkin's lymphoma cases, underscoring the urgent need for advancements in therapeutic solutions. This increasing incidence serves as a catalyst for the growth of the diffuse large B-cell lymphoma therapeutics market.

The anticipated growth of the diffuse large B-cell lymphoma (DLBCL) therapeutics market is closely tied to the increasing adoption of personalized medicine. Personalized medicine, an innovative healthcare approach, tailors medical interventions to the unique characteristics of each patient, including genetic and molecular profiles. This approach facilitates the development of targeted therapies specifically addressing the heterogeneity of DLBCL subtypes. Biomarker-driven treatment strategies and companion diagnostics play a pivotal role in identifying patients likely to benefit from specific therapies, thus enhancing overall treatment efficacy. Noteworthy is the fact that in 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% (12 NMEs) classified as personalized medicines by the Personalized Medicine Coalition (PMC). The increasing adoption of personalized medicine emerges as a significant driver for the growth of the diffuse large B-cell lymphoma therapeutics market.

The diffuse large B-cell lymphoma (DLBCL) therapeutics market is witnessing a notable trend marked by the increasing emphasis on the development of therapeutic drugs. Key players within this market are actively engaged in the research and development of novel drugs to bolster their standing and competitiveness. A pertinent example is Bristol-Myers Squibb, a prominent US-based pharmaceutical company dedicated to drug research and development. In June 2022, the company secured approval from the US FDA for CAR T Cell Therapy Breyanzi. This approval extended the application of Breyanzi to encompass the treatment of patients with diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma (LBCL), and relapsed or refractory large B-cell lymphoma. Breyanzi, characterized as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, is designed to cater to a diverse patient population, including those with primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma grade 3B.

A pivotal strategy employed by major players in the diffuse large B-cell lymphoma (DLBCL) therapeutics market involves the continuous development of new drugs to secure a competitive advantage. Illustratively, in June 2023, MINJUVI (tafasitamab), a product of Specialised Therapeutics Asia Pte Ltd (STA), a Singapore-based biopharmaceutical company, received approval from the Therapeutic Goods Administration (TGA). Indicated for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant (ASCT), MINJUVI, in combination with lenalidomide, functions as a CD19-targeting immunotherapy, triggering an immune response against B-cell lymphoma cells. The drug has demonstrated a favorable side effect profile and achieved high response rates in patients with relapsed disease. Its approval through a provisional regulatory pathway and participation in the Modified Project Orbis initiative underscore the concerted efforts to expedite availability for Australian patients. The decision was informed by positive data from the Phase 2 L-MIND study, with ongoing approval contingent on findings from the confirmatory Phase 3 frontMIND study.

In August 2022, Ipsen, a prominent biopharmaceutical company based in France, successfully acquired Epizyme Inc. The financial details of the acquisition were not disclosed. This acquisition has proven instrumental in empowering Ipsen to diversify and enhance its oncology portfolio. Notably, the integration of Epizyme's Tazverik, a groundbreaking EZH2 inhibitor, has fortified Ipsen's commitment to providing innovative treatments. This strategic expansion has further augmented Ipsen's capabilities within the oncology sector, positioning the company as a key player in delivering advanced therapeutic solutions. Epizyme Inc., a US-based biopharmaceutical company specializing in the development and marketing of epigenetic therapies for cancer and other diseases, brought valuable expertise and assets to Ipsen through this strategic acquisition.

Major companies operating in the diffuse large B-cell lymphoma therapeutics market include Novartis AG, Pfizer Inc., Merck & Co Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche AG, CTI BioPharma Corp., Celltrion Healthcare Co Ltd., Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences Inc., Seagen Inc., Kite Pharma Inc., ADC Therapeutics SA, Bayer AG, Xencor Inc., Autolus Therapeutics plc, Allogene Therapeutics Inc., Spectrum Pharmaceuticals Inc., AstraZeneca PLC, Aptevo Therapeutics Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Celgene Corporation, Eli Lilly and Company, Sanofi SA, Seattle Genetics Inc., Karyopharm Therapeutics Inc., TG Therapeutics Inc., MorphoSys AG

North America was the largest region in the global diffuse large B-cell lymphoma therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diffuse large b-cell lymphoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the diffuse large b-cell lymphoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The diffuse large B-cell lymphoma therapeutics market consists of revenues earned by entities by providing R-CHOP (rituximab (Rituxan), cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine (Oncovin), and prednisone therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The diffuse large B-cell lymphoma therapeutics market also includes sales of diagnostic devices, radiation therapy equipment, surgical instruments, and devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diffuse Large B-cell Lymphoma Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diffuse large b-cell lymphoma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diffuse large b-cell lymphoma therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The diffuse large b-cell lymphoma therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Cisplatin; Carboplatin; 5-fluorouracil; Docetaxel; Paclitaxel; Methotrexate; Other Drugs
• 2) By Therapy: Targeted Therapy; Immunotherapy; Chemotherapy; Other Therapies
• 3) By Route of Administration: Oral; Parenteral; Other Routes
• 4) By End User: Hospitals; Clinics; Other End-Users
• Subsegments:
• 1) By Cisplatin: Injection Formulations; Combination Therapies
• 2) By Carboplatin: Injection Formulations; Combination Therapies
• 3) By 5-Fluorouracil: Injection Formulations; Oral Formulations
• 4) By Docetaxel: Injection Formulations; Combination Therapies
• 5) By Paclitaxel: Injection Formulations; Combination Therapies
• 6) By Methotrexate: Injection Formulations; Oral Formulations; Combination Therapies
• 7) By Other Drugs: Monoclonal Antibodies; Targeted Therapies; Immunotherapies; Experimental Therapies
• Companies Mentioned: Novartis AG; Pfizer Inc.; Merck & Co Inc.; GlaxoSmithKline plc; F. Hoffmann-La Roche AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Diffuse Large B-cell Lymphoma Therapeutics Market Characteristics

3. Diffuse Large B-cell Lymphoma Therapeutics Market Trends And Strategies

4. Diffuse Large B-cell Lymphoma Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Diffuse Large B-cell Lymphoma Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Diffuse Large B-cell Lymphoma Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Diffuse Large B-cell Lymphoma Therapeutics Market Growth Rate Analysis
• 5.4. Global Diffuse Large B-cell Lymphoma Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Diffuse Large B-cell Lymphoma Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Diffuse Large B-cell Lymphoma Therapeutics Total Addressable Market (TAM)

6. Diffuse Large B-cell Lymphoma Therapeutics Market Segmentation

• 6.1. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cisplatin
• Carboplatin
• 5-fluorouracil
• Docetaxel
• Paclitaxel
• Methotrexate
• Other Drugs
• 6.2. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Other Therapies
• 6.3. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes
• 6.4. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End-Users
• 6.5. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Sub-Segmentation Of Cisplatin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injection Formulations
• Combination Therapies
• 6.6. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Sub-Segmentation Of Carboplatin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injection Formulations
• Combination Therapies
• 6.7. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Sub-Segmentation Of 5-Fluorouracil, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injection Formulations
• Oral Formulations
• 6.8. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Sub-Segmentation Of Docetaxel, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injection Formulations
• Combination Therapies
• 6.9. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Sub-Segmentation Of Paclitaxel, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injection Formulations
• Combination Therapies
• 6.10. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Sub-Segmentation Of Methotrexate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injection Formulations
• Oral Formulations
• Combination Therapies
• 6.11. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Targeted Therapies
• Immunotherapies
• Experimental Therapies

7. Diffuse Large B-cell Lymphoma Therapeutics Market Regional And Country Analysis

• 7.1. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Diffuse Large B-cell Lymphoma Therapeutics Market

• 8.1. Asia-Pacific Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Diffuse Large B-cell Lymphoma Therapeutics Market

• 9.1. China Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• 9.2. China Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Diffuse Large B-cell Lymphoma Therapeutics Market

• 10.1. India Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Diffuse Large B-cell Lymphoma Therapeutics Market

• 11.1. Japan Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• 11.2. Japan Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Diffuse Large B-cell Lymphoma Therapeutics Market

• 12.1. Australia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Diffuse Large B-cell Lymphoma Therapeutics Market

• 13.1. Indonesia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Diffuse Large B-cell Lymphoma Therapeutics Market

• 14.1. South Korea Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• 14.2. South Korea Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Diffuse Large B-cell Lymphoma Therapeutics Market

• 15.1. Western Europe Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• 15.2. Western Europe Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Diffuse Large B-cell Lymphoma Therapeutics Market

• 16.1. UK Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Diffuse Large B-cell Lymphoma Therapeutics Market

• 17.1. Germany Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Diffuse Large B-cell Lymphoma Therapeutics Market

• 18.1. France Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Diffuse Large B-cell Lymphoma Therapeutics Market

• 19.1. Italy Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Diffuse Large B-cell Lymphoma Therapeutics Market

• 20.1. Spain Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Diffuse Large B-cell Lymphoma Therapeutics Market

• 21.1. Eastern Europe Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• 21.2. Eastern Europe Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Diffuse Large B-cell Lymphoma Therapeutics Market

• 22.1. Russia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Diffuse Large B-cell Lymphoma Therapeutics Market

• 23.1. North America Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• 23.2. North America Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Diffuse Large B-cell Lymphoma Therapeutics Market

• 24.1. USA Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• 24.2. USA Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Diffuse Large B-cell Lymphoma Therapeutics Market

• 25.1. Canada Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• 25.2. Canada Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Diffuse Large B-cell Lymphoma Therapeutics Market

• 26.1. South America Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• 26.2. South America Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Diffuse Large B-cell Lymphoma Therapeutics Market

• 27.1. Brazil Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Diffuse Large B-cell Lymphoma Therapeutics Market

• 28.1. Middle East Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• 28.2. Middle East Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Diffuse Large B-cell Lymphoma Therapeutics Market

• 29.1. Africa Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• 29.2. Africa Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Diffuse Large B-cell Lymphoma Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Diffuse Large B-cell Lymphoma Therapeutics Market Competitive Landscape
• 30.2. Diffuse Large B-cell Lymphoma Therapeutics Market Company Profiles
  • 30.2.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

31. Diffuse Large B-cell Lymphoma Therapeutics Market Other Major And Innovative Companies

• 31.1. CTI BioPharma Corp.
• 31.2. Celltrion Healthcare Co Ltd.
• 31.3. Bristol-Myers Squibb Company
• 31.4. AbbVie Inc.
• 31.5. Gilead Sciences Inc.
• 31.6. Seagen Inc.
• 31.7. Kite Pharma Inc.
• 31.8. ADC Therapeutics SA
• 31.9. Bayer AG
• 31.10. Xencor Inc.
• 31.11. Autolus Therapeutics plc
• 31.12. Allogene Therapeutics Inc.
• 31.13. Spectrum Pharmaceuticals Inc.
• 31.14. AstraZeneca PLC
• 31.15. Aptevo Therapeutics Inc.

32. Global Diffuse Large B-cell Lymphoma Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Diffuse Large B-cell Lymphoma Therapeutics Market

34. Recent Developments In The Diffuse Large B-cell Lymphoma Therapeutics Market

35. Diffuse Large B-cell Lymphoma Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Diffuse Large B-cell Lymphoma Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Diffuse Large B-cell Lymphoma Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Diffuse Large B-cell Lymphoma Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer